BAUSCH + LOMB CORP (BLCO) Stock News
NYSE:BLCO - New York Stock Exchange, Inc. - CA0717051076 - Common Stock - Currency: USD
BLCO Latest News, Press Relases and Analysis
Bausch + Lomb Will Release Second-Quarter 2025 Financial Results on July 30 and Hold Investor Day on Nov. 13
Mentions: BLCO.CA
Bausch + Lomb Announces Closing of Upsized €675 Million Senior Secured Notes Offering and Partial Credit Agreement Refinancing, Including Upsized $2.325 Billion Term Loan Facility
Mentions: BLCO.CA
Securities Fraud Investigation Into Bausch + Lomb Corporation (BLCO) Continues – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
Bausch + Lomb Corporation (BLCO) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
Barclays Cut Bausch & Lomb Target to $16, Keeping Rating Neutral in Early June
Barclays lowered its price target on Bausch & Lomb (NYSE: BLCO) from $19 to $16 on June 6, maintaining an Equalweight rating. The revision reflects a more cautious outlook on the company’s near-term financial performance. The firm trimmed its next twelve-month EBITDA forecast to $996 million, down from $1.04 billion. As a result, the valuation […]
Mentions: BHC
Bausch + Lomb Announces Pricing of Upsized Senior Secured Notes Offering
Mentions: BLCO.CA
Bausch + Lomb Announces Launch of Senior Secured Notes Offering and Refinancing of Credit Agreement
Mentions: BLCO.CA
BLCO Investors Have Opportunity to Join Bausch + Lomb Corporation Fraud Investigation with the Schall Law Firm
Bausch + Lomb Launches Blink® Nourish Lubricating Eye Drops and Blink Boost Lubricating Eye Drops in the United States
Mentions: BLCO.CA
Innovations in Imaging, such as AI-Enhanced Retinal & Fundus Camera Systems are Booming Along with Revenue Opportunities
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bausch + Lomb Corporation - BLCO
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Bausch + Lomb Corporation ("Bausch + Lomb" or the "Company") (NYSE: BLCO). Such...
Alcon Secures First FDA Approval Since Novartis Spin-Off In 2019
FDA approves Alcon's Tryptyr for dry eye disease, backed by Phase 3 trials showing strong efficacy in increasing natural tear production.
Bausch + Lomb to Participate in the 2025 Jefferies Global Healthcare Conference
Mentions: BLCO.CA
Bausch + Lomb Announces 2025 Annual Meeting of Shareholders Results
Mentions: BLCO.CA
Bausch + Lomb Launches New LUMIFY® Preservative Free Redness Reliever Eye Drops in the United States
Mentions: BLCO.CA
Icahn Ramps Up Bets On Genes And Jets: Illumina Stake Jumps 450%, JetBlue Holding Grow 90%
Carl Icahn boosts holdings in Illumina and JetBlue, showing confidence in biotech and airlines. He also trims exposure to Southwest Gas Holdings.
Bausch + Lomb Launches Zenlens® CHROMA HOA™ in the United States
Mentions: BLCO.CA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bausch + Lomb Corporation - BLCO
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Bausch + Lomb Corporation ("Bausch + Lomb" or the "Company") (NYSE: BLCO). Such...
Bausch + Lomb Corporation (BLCO) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
Securities Fraud Investigation Into Bausch + Lomb Corporation (BLCO) Announced – Investors Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz
Bausch + Lomb Receives European CE Mark Approval for Preloaded LuxLife® Full Range of Vision Intraocular Lens
Mentions: BLCO.CA